Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients
Background: Cardiovascular disease in Asia has reached epidemic proportions in recent years. Use of drug eluting stents in Asians has rapidly expanded with varying penetration rates across different countries. The XIENCE V® INDIA Study included ‘real world’ patients who underwent XIENCE V® stent imp...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-05-01
|
| Series: | Indian Heart Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0019483214001217 |
| _version_ | 1819000158612881408 |
|---|---|
| author | Ashok Seth Tejas M. Patel Marrianne Stuteville Ravindra Kumar Ajit S. Mullasari Upendra Kaul Rony Mathew A. Sreenivas Kumar Shih-Wa Ying Krishnankutty Sudhir |
| author_facet | Ashok Seth Tejas M. Patel Marrianne Stuteville Ravindra Kumar Ajit S. Mullasari Upendra Kaul Rony Mathew A. Sreenivas Kumar Shih-Wa Ying Krishnankutty Sudhir |
| author_sort | Ashok Seth |
| collection | DOAJ |
| description | Background: Cardiovascular disease in Asia has reached epidemic proportions in recent years. Use of drug eluting stents in Asians has rapidly expanded with varying penetration rates across different countries. The XIENCE V® INDIA Study included ‘real world’ patients who underwent XIENCE V® stent implantation to assess short and intermediate term outcomes in Indian patients with diverse risk factors.
Objective: To evaluate 3-year clinical outcomes in a cohort of ‘real world’ Indian patients with CAD being treated with XIENCE V® Everolimus Eluting Coronary Stent System.
Methods: 1000 patients were enrolled from 18 sites in India between June 2008 and March 2009. Patients were included if their index procedures were completed using only XIENCE V®. There were no clinical or angiographic exclusions. An independent Clinical Events Committee adjudicated all endpoint-related events. The primary endpoint was stent thrombosis rate annually through to 3 years as defined by the Academic Research Consortium criteria. The co-primary endpoint was the composite rate of cardiac death and myocardial infarction at 1 year.
Results: At 1-year the primary endpoint of definite/probable stent thrombosis rate was 0.51%. No additional very late stent thrombosis was reported through a 3-year follow up. The composite endpoint of cardiac death and any myocardial infarction was 1.9%, 2.7% and 3.1% at 1, 2 and 3 years respectively.
Conclusion: Despite the high risk population of coronary artery disease, the use of XIENCE V® in 'real world' Indian patients was associated with very low clinical event rates upto three years of follow up. |
| first_indexed | 2024-12-20T22:28:52Z |
| format | Article |
| id | doaj.art-5547f0aece684850baf56e6bd3a47db8 |
| institution | Directory Open Access Journal |
| issn | 0019-4832 |
| language | English |
| last_indexed | 2024-12-20T22:28:52Z |
| publishDate | 2014-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Indian Heart Journal |
| spelling | doaj.art-5547f0aece684850baf56e6bd3a47db82022-12-21T19:24:45ZengElsevierIndian Heart Journal0019-48322014-05-0166330230810.1016/j.ihj.2014.03.007Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patientsAshok Seth0Tejas M. Patel1Marrianne Stuteville2Ravindra Kumar3Ajit S. Mullasari4Upendra Kaul5Rony Mathew6A. Sreenivas Kumar7Shih-Wa Ying8Krishnankutty Sudhir9Chairman – Cardiovascular Sciences & Chief Cardiologist, Fortis Escorts Heart Institute, Okhla Road, New Delhi 110025, IndiaAppex Heart Institute, Ahmedabad, IndiaAbbott Vascular, Diegem, BelgiumAbbott Vascular, Bangalore, IndiaInstitute of Cardiovascular Disease, Madras Medical Mission, Chennai, IndiaFortis Escorts Heart Institute, New Delhi, IndiaLisie Hospital, Kochi, IndiaContinental Institute of Cardiovascular Sciences, Hyderabad, IndiaAbbott Vascular, Santa Clara, USAAbbott Vascular, Santa Clara, USABackground: Cardiovascular disease in Asia has reached epidemic proportions in recent years. Use of drug eluting stents in Asians has rapidly expanded with varying penetration rates across different countries. The XIENCE V® INDIA Study included ‘real world’ patients who underwent XIENCE V® stent implantation to assess short and intermediate term outcomes in Indian patients with diverse risk factors. Objective: To evaluate 3-year clinical outcomes in a cohort of ‘real world’ Indian patients with CAD being treated with XIENCE V® Everolimus Eluting Coronary Stent System. Methods: 1000 patients were enrolled from 18 sites in India between June 2008 and March 2009. Patients were included if their index procedures were completed using only XIENCE V®. There were no clinical or angiographic exclusions. An independent Clinical Events Committee adjudicated all endpoint-related events. The primary endpoint was stent thrombosis rate annually through to 3 years as defined by the Academic Research Consortium criteria. The co-primary endpoint was the composite rate of cardiac death and myocardial infarction at 1 year. Results: At 1-year the primary endpoint of definite/probable stent thrombosis rate was 0.51%. No additional very late stent thrombosis was reported through a 3-year follow up. The composite endpoint of cardiac death and any myocardial infarction was 1.9%, 2.7% and 3.1% at 1, 2 and 3 years respectively. Conclusion: Despite the high risk population of coronary artery disease, the use of XIENCE V® in 'real world' Indian patients was associated with very low clinical event rates upto three years of follow up.http://www.sciencedirect.com/science/article/pii/S0019483214001217Coronary artery diseaseDrug-eluting stentXIENCE V®Percutaneous coronary interventionXIENCE V® INDIA |
| spellingShingle | Ashok Seth Tejas M. Patel Marrianne Stuteville Ravindra Kumar Ajit S. Mullasari Upendra Kaul Rony Mathew A. Sreenivas Kumar Shih-Wa Ying Krishnankutty Sudhir Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients Indian Heart Journal Coronary artery disease Drug-eluting stent XIENCE V® Percutaneous coronary intervention XIENCE V® INDIA |
| title | Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients |
| title_full | Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients |
| title_fullStr | Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients |
| title_full_unstemmed | Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients |
| title_short | Three-year data from the XIENCE V® INDIA study: Safety and efficacy of XIENCE V® in 1000 real world Indian patients |
| title_sort | three year data from the xience v r india study safety and efficacy of xience v r in 1000 real world indian patients |
| topic | Coronary artery disease Drug-eluting stent XIENCE V® Percutaneous coronary intervention XIENCE V® INDIA |
| url | http://www.sciencedirect.com/science/article/pii/S0019483214001217 |
| work_keys_str_mv | AT ashokseth threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT tejasmpatel threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT marriannestuteville threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT ravindrakumar threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT ajitsmullasari threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT upendrakaul threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT ronymathew threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT asreenivaskumar threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT shihwaying threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients AT krishnankuttysudhir threeyeardatafromthexiencevindiastudysafetyandefficacyofxiencevin1000realworldindianpatients |